Literature DB >> 20553960

Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions.

M Kuppermann1, J Melnikow, C Slee, D J Tancredi, S Kulasingam, S Birch, L J Helms, A M Bayoumi, G F Sawaya.   

Abstract

OBJECTIVES: Data are lacking on how women view alternative approaches to surveillance for cervical cancer after treatment of high-grade cervical intraepithelial neoplasia. We measured and compared patient preferences (utilities) for scenarios with varying surveillance strategies and outcomes to inform guidelines and cost-effectiveness analyses of post-treatment surveillance options.
METHODS: English- or Spanish-speaking women who had received an abnormal Pap test result within the past 2 years were recruited from general gynecology and colposcopy clinics and newspaper and online advertisements in 2007 and 2008. Participation consisted of one face-to-face interview, during which utilities for 11 different surveillance scenarios and their associated outcomes were elicited using the time tradeoff metric. A sociodemographic questionnaire also was administered.
RESULTS: 65 women agreed to participate and successfully completed the preference elicitation exercises. Mean utilities ranged from 0.989 (undergoing only a Pap test, receiving normal results) to 0.666 (invasive cervical cancer treated with radical hysterectomy or radiation and chemotherapy). Undergoing both Pap and HPV tests and receiving normal/negative results had a lower mean utility (0.953) then undergoing only a Pap test and receiving normal results (0.989). Having both tests and receiving normal Pap but positive HPV results was assigned an even lower mean utility (0.909). 15.9% of the respondents gave higher utility scores to the Pap plus HPV testing scenario (with normal/negative results) than to the "Pap test alone" scenario (with normal results), while 17.5% gave the Pap test alone scenario a higher utility score.
CONCLUSIONS: Preferences for outcomes ending with normal results but involving alternative surveillance processes differ substantially. The observed differences in utilities have important implications for clinical guidelines and cost-effectiveness analyses. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20553960      PMCID: PMC2926130          DOI: 10.1016/j.ygyno.2010.05.002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

Review 1.  Measurement of health state utilities for economic appraisal.

Authors:  G W Torrance
Journal:  J Health Econ       Date:  1986-03       Impact factor: 3.883

2.  International incidence rates of invasive cervical cancer after introduction of cytological screening.

Authors:  L Gustafsson; J Pontén; M Zack; H O Adami
Journal:  Cancer Causes Control       Date:  1997-09       Impact factor: 2.506

3.  Abnormal outcomes following cervical cancer screening: event duration and health utility loss.

Authors:  Ralph P Insinga; Andrew G Glass; Evan R Myers; Brenda B Rush
Journal:  Med Decis Making       Date:  2007-06-21       Impact factor: 2.583

4.  Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  B Gandek; J E Ware; N K Aaronson; G Apolone; J B Bjorner; J E Brazier; M Bullinger; S Kaasa; A Leplege; L Prieto; M Sullivan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

5.  ACOG Practice Bulletin no. 109: Cervical cytology screening.

Authors: 
Journal:  Obstet Gynecol       Date:  2009-12       Impact factor: 7.661

6.  Management of the low-grade abnormal Pap smear: What are women's preferences?

Authors:  Joy Melnikow; Miriam Kuppermann; Stephen Birch; Benjamin K S Chan; Jim Nuovo
Journal:  J Fam Pract       Date:  2002-10       Impact factor: 0.493

7.  A utility maximization model for evaluation of health care programs.

Authors:  G W Torrance; W H Thomas; D L Sackett
Journal:  Health Serv Res       Date:  1972       Impact factor: 3.402

8.  The minimally clinically important difference in generic utility-based measures.

Authors:  Robert M Kaplan
Journal:  COPD       Date:  2005-03       Impact factor: 2.409

9.  How do women of diverse backgrounds value prenatal testing outcomes?

Authors:  Miriam Kuppermann; Robert F Nease; Elena Gates; Lee A Learman; Bruce Blumberg; Virginia Gildengorin; A Eugene Washington
Journal:  Prenat Diagn       Date:  2004-06       Impact factor: 3.050

10.  Psychological side effects of breast cancer screening.

Authors:  C Lerman; B Trock; B K Rimer; C Jepson; D Brody; A Boyce
Journal:  Health Psychol       Date:  1991       Impact factor: 4.267

View more
  3 in total

1.  Patient preferences for side effects associated with cervical cancer treatment.

Authors:  Charlotte Sun; Alaina J Brown; Anuja Jhingran; Michael Frumovitz; Lois Ramondetta; Diane C Bodurka
Journal:  Int J Gynecol Cancer       Date:  2014-07       Impact factor: 3.437

2.  Estimation of utility weights for human papilloma virus-related health states according to disease severity.

Authors:  Minsu Ock; Jeong-Yeol Park; Woo-Seung Son; Hyeon-Jeong Lee; Seon-Ha Kim; Min-Woo Jo
Journal:  Health Qual Life Outcomes       Date:  2016-11-28       Impact factor: 3.186

3.  A survey of population-based utility scores for cervical cancer prevention.

Authors:  Leonardo Simonella; Kirsten Howard; Karen Canfell
Journal:  BMC Res Notes       Date:  2014-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.